Literature DB >> 24298477

A Clinical Study of Subtype-based Prevalence of Dry Eye.

Aditya Rege1, Varsha Kulkarni, Neelam Puthran, Tejaswini Khandgave.   

Abstract

INTRODUCTION: Dry Eye is a multifactorial disease of the tearfilm and the ocular surface which may be due to reduced tear production or excessive tear evaporation resulting in discomfort, visual disturbance, and tear film instability with a potential damage to the ocular surface. Various population-based studies have been done to find out the prevalence and the magnitude of the problem. Women Health Study reported prevalence of 7.8% after screening 36995 subjects above 49 years by interview. The prevalence reported by Blue Mountain Study was 15.3% .The Beaver Dam Study and Shiphai Eye studies are other studies reporting prevalence of 14.5% and 33.7% respectively. McMonnies questionnaire is a widely used screening instrument for Dry-Eye syndromes with sensitivity reportedly varying between 87% and 98% and specificity between 87% and 97%. Prevalence studies use McMonnie's questionnaire for screening individuals for Dry Eye, whereafter tests like Schirmer's test, Tear Film Break Up Time test, Rose Bengal test, Lissamine Green test and Meibomian Gland Dysfunction test are useful for further evaluation. While these tests help to differentiate the subtypes of Dry Eye such as Lipid Anomaly Dry Eye, Aqueous Tear Deficiency and Mucin Layer Deficiency, however, their sensitivity and specificity has not been widely studied. Additionally, very few studies have reported the prevalence of the various subtypes of Dry Eye. AIM AND
OBJECTIVES: To determine the subtype-based prevalence of Dry Eye, to study the specificity and sensitivity of clinical tests for Dry Eye and to correlate McMonnies questionnaire with Dry Eye tests results.
MATERIAL AND METHODS: A prospective, cross-sectional, observational study, duly approved by the Institutional Ethics Committee, was conducted from October 2010 to April 2012. A total of 4750 subjects above 18 yrs of age were screened by the McMonnies questionnaire. Respondents having a score greater than 14.5 were subjected to clinical Dry Eye tests. The data obtained was analyzed using chi-square test. p value < 0.005 was considered statistically significant.The specificity and sensitivity of each clinical test was calculated using Schirmer's test as gold standard.
RESULTS: The prevalence of Dry Eye was 15.4%, with a female preponderance (p = 0.01) and a significant increase with age above 60 years was noted (p<0.0001). Tear Film Break Up Time was the most reliable test with a good sensitivity (68.85%) and specificity (78.32%). Lipid Anomaly Dry Eye was the most prevalent (14.48%) followed by Aqueous Tear Deficiency (13.36%) and Mucin Layer Deficiency (3.51%). A positive correlation between McMonnies score and severity of Dry Eye was seen.
CONCLUSION: This study suggests that Lipid Layer Anomaly is the most prevalent subtype in Dry Eye. Tear Film Break Up Time test is the most likely test to diagnose mild Dry Eye. McMonies Questionnaire can be effectively used for screening of a large population. Tear Film Break Up Time was found to have better sensitivity as well as specificity than other tests used for diagnosing Dry Eye.

Entities:  

Keywords:  Dry Eye; McMonnies Questionnaire

Year:  2013        PMID: 24298477      PMCID: PMC3843414          DOI: 10.7860/JCDR/2013/6089.3472

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

1.  Prevalence of dry eye subtypes in clinical optometry practice.

Authors:  J M Albietz
Journal:  Optom Vis Sci       Date:  2000-07       Impact factor: 1.973

2.  Optimum dry eye classification using questionnaire responses.

Authors:  C McMonnies; A Ho; D Wakefield
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

3.  A non-invasive instrument for clinical assessment of the pre-corneal tear film stability.

Authors:  L S Mengher; A J Bron; S R Tonge; D J Gilbert
Journal:  Curr Eye Res       Date:  1985-01       Impact factor: 2.424

4.  Schirmer's test. A closer look.

Authors:  T E Clinch; D A Benedetto; N T Felberg; P R Laibson
Journal:  Arch Ophthalmol       Date:  1983-09

5.  Prevalence of and risk factors for dry eye syndrome.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Arch Ophthalmol       Date:  2000-09

6.  Reliability and validity of the Ocular Surface Disease Index.

Authors:  R M Schiffman; M D Christianson; G Jacobsen; J D Hirsch; B L Reis
Journal:  Arch Ophthalmol       Date:  2000-05

7.  Prevalence of dry eye syndrome among US women.

Authors:  Debra A Schaumberg; David A Sullivan; Julie E Buring; M Reza Dana
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

8.  Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study.

Authors:  Ee-Munn Chia; Paul Mitchell; Elena Rochtchina; Anne J Lee; Rita Maroun; Jie Jin Wang
Journal:  Clin Exp Ophthalmol       Date:  2003-06       Impact factor: 4.207

Review 9.  Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia.

Authors:  A J Lee; J Lee; S-M Saw; G Gazzard; D Koh; D Widjaja; D T H Tan
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

10.  Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study.

Authors:  Pei-Yu Lin; Su-Ying Tsai; Ching-Yu Cheng; Jorn-Hon Liu; Pesus Chou; Wen-Ming Hsu
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

View more
  17 in total

1.  Dyslipidemia and its association with meibomian gland dysfunction.

Authors:  Puneet S Braich; Mary K Howard; Jorawer S Singh
Journal:  Int Ophthalmol       Date:  2015-10-29       Impact factor: 2.031

2.  In vivo detection of clinically non-apparent ocular surface inflammation in patients with meibomian gland dysfunction-associated refractory dry eye symptoms: a pilot study.

Authors:  Y Qazi; A Kheirkhah; C Blackie; A Cruzat; M Trinidad; C Williams; D R Korb; P Hamrah
Journal:  Eye (Lond)       Date:  2015-06-19       Impact factor: 3.775

3.  Prevalence, Severity, and Treatment Outcomes of Meibomian Gland Dysfunction in Patients With Dry Eye Symptoms at a Tertiary Care Center in South India.

Authors:  Jayanti Singh; Yamini Priya; Vivek Bhat
Journal:  Cureus       Date:  2022-06-07

4.  Effect of a Mediterranean dietary pattern and vitamin D levels on Dry Eye syndrome.

Authors:  Anat Galor; Hannah Gardener; Bozorgmehr Pouyeh; William Feuer; Hermes Florez
Journal:  Cornea       Date:  2014-05       Impact factor: 2.651

5.  Prevalence of dry eye syndrome after a three-year exposure to a clean room.

Authors:  Hyun A Cho; Jae Jung Cheon; Jong Seok Lee; Soo Young Kim; Seong Sil Chang
Journal:  Ann Occup Environ Med       Date:  2014-09-03

6.  Evaluation of dry eye findings in patients with vitiligo.

Authors:  Aysun Sanal Dogan; Damla Atacan; Selda Pelin Kartal Durmazlar; Mutlu Acar; Canan Gurdal
Journal:  Pak J Med Sci       Date:  2015       Impact factor: 1.088

7.  Diagnostic Performance of McMonnies Questionnaire as a Screening Survey for Dry Eye: A Multicenter Analysis.

Authors:  Yuxin Guo; Rongmei Peng; Kang Feng; Jing Hong
Journal:  J Ophthalmol       Date:  2016-05-15       Impact factor: 1.909

8.  Association Between Serum Levels of Testosterone and Estradiol With Meibomian Gland Assessments in Postmenopausal Women.

Authors:  Anna F Ablamowicz; Jason J Nichols; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-02       Impact factor: 4.799

9.  Corneal and conjunctival sensitivity in rosacea patients.

Authors:  Nurgül Örnek; Ayşe Anıl Karabulut; Kemal Örnek; Zafer Onaran; Gülşah Usta
Journal:  Saudi J Ophthalmol       Date:  2015-09-11

10.  Interdisciplinary, Comprehensive Oral and Ocular Evaluation of Patients with Primary Sjögren's Syndrome.

Authors:  Behzod Tashbayev; Shermin Rusthen; Alix Young; Bente Brokstad Herlofson; Lene Hystad Hove; Preet Bano Singh; Morten Rykke; Lara Adnan Aqrawi; Xiangjun Chen; Øygunn Aass Utheim; Tor Paaske Utheim; Øyvind Palm; Janicke Liaaen Jensen
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.